Travere Therapeutics Ownership 2024 | Who Owns Travere Therapeutics Now?
Institutional Ownership
20.41%
Insider Ownership
0.73%
Retail Ownership
78.87%
Institutional Holders
52.00
Travere Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BLACKROCK INC. | 9.86% | 0.00% | 7,644,789 | -151,977 | -1.95% | 62,840,164 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 9.68% | 0.78% | 7,500,000 | - | - | 61,650,000 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 9.51% | 1.81% | 7,370,000 | - | - | 60,581,400 | Jun 30, 2024 |
| VANGUARD GROUP INC | 8.54% | 0.00% | 6,619,756 | 353,927 | 5.65% | 54,414,394 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 5.78% | 1.11% | 4,482,265 | 1,057,447 | 30.88% | 36,844,218 | Jun 30, 2024 |
| MACQUARIE GROUP LTD | 5.64% | 0.04% | 4,367,830 | -245,229 | -5.32% | 35,904,000 | Jun 30, 2024 |
| STATE STREET CORP | 4.53% | 0.00% | 3,510,677 | -3,098,019 | -46.88% | 28,857,765,000 | Jun 30, 2024 |
| MORGAN STANLEY | 4.50% | 0.00% | 3,489,662 | -37,958 | -1.08% | 28,685,021 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 3.81% | 0.01% | 2,949,335 | 747,406 | 33.94% | 24,243,534 | Jun 30, 2024 |
| ASSENAGON ASSET MANAGEMENT S.A. | 2.86% | 0.04% | 2,214,099 | 1,995,419 | 912.48% | 18,199,894 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 2.84% | 0.03% | 2,203,814 | -658,200 | -23.00% | 18,115,351 | Jun 30, 2024 |
| KYNAM CAPITAL MANAGEMENT, LP | 2.61% | 1.28% | 2,021,659 | 21,659 | 1.08% | 16,618,037 | Jun 30, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2.44% | 0.06% | 1,889,844 | 765,159 | 68.03% | 15,534,518 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 2.42% | 0.00% | 1,878,954 | 169,321 | 9.90% | 15,445,002 | Jun 30, 2024 |
| FINEPOINT CAPITAL LP | 2.29% | 4.15% | 1,776,728 | 127,507 | 7.73% | 14,604,704 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.15% | 0.00% | 1,666,301 | 105,413 | 6.75% | 13,699,973 | Jun 30, 2024 |
| EMERALD ADVISERS, LLC | 2.11% | 0.56% | 1,637,146 | -112,255 | -6.42% | 13,457,340 | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 1.98% | 0.01% | 1,533,072 | -311,591 | -16.89% | 12,601,852 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 1.65% | 0.10% | 1,276,878 | 1,276,878 | 100.00% | 10,495,937 | Jun 30, 2024 |
| EVERSEPT PARTNERS, LP | 1.41% | 0.61% | 1,091,165 | 135,547 | 14.18% | 8,969,376 | Jun 30, 2024 |
Travere Therapeutics's largest institutional shareholder is BLACKROCK INC., holding 9.86% of the company's total share outstanding, currently valued at $62.84M. The top 10 institutional shareholders own together 64.71% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| FINEPOINT CAPITAL LP | 2.29% | 4.15% | 1,776,728 | 127,507 | 7.73% | 14,604,704 | Jun 30, 2024 |
| EXOME ASSET MANAGEMENT LLC | 0.57% | 3.17% | 443,379 | 80,892 | 22.32% | 3,644,576 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 9.51% | 1.81% | 7,370,000 | - | - | 60,581,400 | Jun 30, 2024 |
| TALBOT FINANCIAL, LLC | 0.08% | 1.67% | 63,546 | 63,546 | 100.00% | 12,921,444 | Jun 30, 2024 |
| KYNAM CAPITAL MANAGEMENT, LP | 2.61% | 1.28% | 2,021,659 | 21,659 | 1.08% | 16,618,037 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 5.78% | 1.11% | 4,482,265 | 1,057,447 | 30.88% | 36,844,218 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 1.25% | 1.07% | 969,892 | 1,472 | 0.15% | 7,972,512 | Jun 30, 2024 |
| BIRCHVIEW CAPITAL, LP | 0.16% | 0.93% | 122,000 | - | - | 1,002,840 | Jun 30, 2024 |
| KNOTT DAVID M JR | 0.34% | 0.87% | 265,966 | 35,000 | 15.15% | 2,186,000 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 9.68% | 0.78% | 7,500,000 | - | - | 61,650,000 | Jun 30, 2024 |
| HIGHVISTA STRATEGIES LLC | 0.28% | 0.66% | 219,416 | - | - | 1,803,600 | Jun 30, 2024 |
| EVERSEPT PARTNERS, LP | 1.41% | 0.61% | 1,091,165 | 135,547 | 14.18% | 8,969,376 | Jun 30, 2024 |
| EMERALD ADVISERS, LLC | 2.11% | 0.56% | 1,637,146 | -112,255 | -6.42% | 13,457,340 | Jun 30, 2024 |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1.21% | 0.41% | 941,265 | -387,116 | -29.14% | 7,737,198 | Jun 30, 2024 |
| PDT PARTNERS, LLC | 0.31% | 0.19% | 238,783 | 43,242 | 22.11% | 1,962,796 | Jun 30, 2024 |
| VIRTUS ETF ADVISERS LLC | 0.06% | 0.18% | 45,490 | 1,340 | 3.04% | 373,928 | Jun 30, 2024 |
| PENNANT INVESTORS, LP | 0.07% | 0.12% | 55,800 | 55,800 | 100.00% | 458,676 | Jun 30, 2024 |
| PALO ALTO INVESTORS LP | 0.14% | 0.11% | 110,719 | - | - | 910,110 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 1.65% | 0.10% | 1,276,878 | 1,276,878 | 100.00% | 10,495,937 | Jun 30, 2024 |
| CRESTLINE MANAGEMENT, LP | 0.13% | 0.07% | 103,353 | 19,454 | 23.19% | 849,562 | Jun 30, 2024 |
The largest Travere Therapeutics shareholder by % of total assets is FINEPOINT CAPITAL LP. The company owns 1.78M shares of Travere Therapeutics (TVTX), representing 4.15% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ASSENAGON ASSET MANAGEMENT S.A. | 2.86% | 0.04% | 2,214,099 | 1,995,419 | 912.48% | 18,199,894 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 1.65% | 0.10% | 1,276,878 | 1,276,878 | 100.00% | 10,495,937 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 5.78% | 1.11% | 4,482,265 | 1,057,447 | 30.88% | 36,844,218 | Jun 30, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2.44% | 0.06% | 1,889,844 | 765,159 | 68.03% | 15,534,518 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 3.81% | 0.01% | 2,949,335 | 747,406 | 33.94% | 24,243,534 | Jun 30, 2024 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.82% | 0.01% | 634,401 | 530,024 | 507.80% | 5,214,776 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 1.01% | 0.00% | 785,295 | 436,135 | 124.91% | 6,455,125 | Jun 30, 2024 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 0.79% | 0.01% | 615,000 | 412,000 | 202.96% | 5,055,300 | Jun 30, 2024 |
| PRUDENTIAL FINANCIAL INC | 0.56% | 0.01% | 435,641 | 370,380 | 567.54% | 3,580,969 | Jun 30, 2024 |
| VANGUARD GROUP INC | 8.54% | 0.00% | 6,619,756 | 353,927 | 5.65% | 54,414,394 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.34% | 0.00% | 266,471 | 254,096 | 2053.30% | 2,190,392 | Jun 30, 2024 |
| GW&K INVESTMENT MANAGEMENT, LLC | 0.66% | 0.04% | 510,126 | 182,347 | 55.63% | 4,193,000 | Jun 30, 2024 |
| TREXQUANT INVESTMENT LP | 0.23% | 0.02% | 174,488 | 174,488 | 100.00% | 1,434,291 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 2.42% | 0.00% | 1,878,954 | 169,321 | 9.90% | 15,445,002 | Jun 30, 2024 |
| STATE OF WISCONSIN INVESTMENT BOARD | 0.36% | 0.01% | 279,104 | 156,572 | 127.78% | 2,294,235 | Jun 30, 2024 |
| EVERSEPT PARTNERS, LP | 1.41% | 0.61% | 1,091,165 | 135,547 | 14.18% | 8,969,376 | Jun 30, 2024 |
| FINEPOINT CAPITAL LP | 2.29% | 4.15% | 1,776,728 | 127,507 | 7.73% | 14,604,704 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.15% | 0.00% | 1,666,301 | 105,413 | 6.75% | 13,699,973 | Jun 30, 2024 |
| AMERIPRISE FINANCIAL INC | 0.78% | 0.00% | 602,108 | 97,788 | 19.39% | 4,949,327 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.19% | 0.00% | 144,901 | 97,020 | 202.63% | 1,190,000 | Jun 30, 2024 |
As of Jun 30 2024, Travere Therapeutics's largest institutional buyer is ASSENAGON ASSET MANAGEMENT S.A.. The company purchased 2.00M stocks of TVTX, valued at $18.20M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STATE STREET CORP | 4.53% | 0.00% | 3,510,677 | -3,098,019 | -46.88% | 28,857,765,000 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 1.22% | 0.00% | 946,601 | -1,454,972 | -60.58% | 7,781,060 | Jun 30, 2024 |
| PICTET ASSET MANAGEMENT HOLDING SA | 1.26% | 0.01% | 977,954 | -1,260,914 | -56.32% | 8,038,782 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 2.84% | 0.03% | 2,203,814 | -658,200 | -23.00% | 18,115,351 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 0.41% | 0.01% | 320,580 | -551,520 | -63.24% | 2,635,164 | Jun 30, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 0.24% | 0.01% | 182,292 | -412,940 | -69.37% | 1,498,440 | Jun 30, 2024 |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1.21% | 0.41% | 941,265 | -387,116 | -29.14% | 7,737,198 | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 1.98% | 0.01% | 1,533,072 | -311,591 | -16.89% | 12,601,852 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.24% | 0.01% | 185,123 | -255,834 | -58.02% | 1,521,710 | Jun 30, 2024 |
| MACQUARIE GROUP LTD | 5.64% | 0.04% | 4,367,830 | -245,229 | -5.32% | 35,904,000 | Jun 30, 2024 |
| UBS GROUP AG | 0.17% | 0.00% | 131,506 | -241,105 | -64.71% | 1,080,979 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.41% | 0.01% | 314,180 | -225,904 | -41.83% | 2,582,560 | Jun 30, 2024 |
| VOYA INVESTMENT MANAGEMENT LLC | 0.03% | 0.00% | 24,942 | -182,840 | -88.00% | 205,023 | Jun 30, 2024 |
| BLACKROCK INC. | 9.86% | 0.00% | 7,644,789 | -151,977 | -1.95% | 62,840,164 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | - | - | - | -125,000 | -100.00% | - | Jun 30, 2024 |
| EMERALD ADVISERS, LLC | 2.11% | 0.56% | 1,637,146 | -112,255 | -6.42% | 13,457,340 | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -112,000 | -100.00% | - | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.52% | 0.01% | 400,000 | -100,000 | -20.00% | 3,288,000 | Jun 30, 2024 |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | - | - | - | -87,000 | -100.00% | - | Jun 30, 2024 |
| LION POINT CAPITAL, LP | - | - | - | -78,000 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, Travere Therapeutics's biggest institutional seller is STATE STREET CORP. The company sold -3.10M shares of TVTX, valued at $28.86B.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| TREXQUANT INVESTMENT LP | 0.23% | 0.02% | 174,488 | 174,488 | 100.00% | 1,434,291 | Jun 30, 2024 |
| BANK OF MONTREAL /CAN/ | 0.10% | 0.00% | 75,919 | 75,919 | 100.00% | 624,813 | Jun 30, 2024 |
| NORGES BANK | 0.09% | 0.00% | 71,000 | 71,000 | 100.00% | 583,620 | Jun 30, 2024 |
| TALBOT FINANCIAL, LLC | 0.08% | 1.67% | 63,546 | 63,546 | 100.00% | 12,921,444 | Jun 30, 2024 |
| HUDSON BAY CAPITAL MANAGEMENT LP | 0.06% | 0.00% | 44,561 | 44,561 | 100.00% | 366,291 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.06% | 0.00% | 44,284 | 44,284 | 100.00% | 364,427 | Jun 30, 2024 |
| ENGINEERS GATE MANAGER LP | 0.05% | 0.01% | 41,760 | 41,760 | 100.00% | 343,267 | Jun 30, 2024 |
| FEDERATED HERMES, INC. | 0.05% | 0.00% | 41,717 | 41,717 | 100.00% | 342,914,000 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.05% | 0.00% | 39,639 | 39,639 | 100.00% | 325,833 | Jun 30, 2024 |
| POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.05% | 0.06% | 35,377 | 35,377 | 100.00% | 290,795 | Jun 30, 2024 |
| VERITION FUND MANAGEMENT LLC | 0.04% | 0.00% | 28,288 | 28,288 | 100.00% | 232,527 | Jun 30, 2024 |
| POINT72 (DIFC) LTD | 0.03% | 0.01% | 21,315 | 21,315 | 100.00% | 175,207 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.03% | 0.00% | 20,700 | 20,700 | 100.00% | 170,154 | Jun 30, 2024 |
| SG AMERICAS SECURITIES, LLC | 0.02% | 0.00% | 16,884 | 16,884 | 100.00% | 139,000 | Jun 30, 2024 |
| NEWEDGE ADVISORS, LLC | 0.02% | 0.00% | 15,253 | 15,253 | 100.00% | 125,380 | Jun 30, 2024 |
| SEI INVESTMENTS CO | 0.02% | 0.00% | 14,226 | 14,226 | 100.00% | 116,887,000 | Jun 30, 2024 |
| DRW SECURITIES, LLC | 0.01% | 0.00% | 11,598 | 11,598 | 100.00% | 95,335 | Jun 30, 2024 |
| MARTINGALE ASSET MANAGEMENT L P | 0.01% | 0.00% | 11,304 | 11,304 | 100.00% | 92,919 | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 0.01% | 0.00% | 11,157 | 11,157 | 100.00% | 91,711 | Jun 30, 2024 |
| AQUATIC CAPITAL MANAGEMENT LLC | 0.00% | 0.00% | 3,100 | 3,100 | 100.00% | 25,482 | Jun 30, 2024 |
| ALLWORTH FINANCIAL LP | 0.00% | - | 568 | 568 | 100.00% | 5,567 | Jun 30, 2024 |
| BESSEMER GROUP INC | 0.00% | - | 334 | 334 | 100.00% | 3,000 | Jun 30, 2024 |
| STEPHENS CONSULTING, LLC | 0.00% | 0.00% | 115 | 115 | 100.00% | 946 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 97 | 97 | 100.00% | 798 | Jun 30, 2024 |
| INNEALTA CAPITAL, LLC | - | 0.00% | 28 | 28 | 100.00% | 230 | Jun 30, 2024 |
Travere Therapeutics's largest new institutional shareholder by number of shares is TREXQUANT INVESTMENT LP, purchased 174.49K shares, valued at $1.43M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | - | - | - | -125,000 | -100.00% | - | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -112,000 | -100.00% | - | Jun 30, 2024 |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | - | - | - | -87,000 | -100.00% | - | Jun 30, 2024 |
| LION POINT CAPITAL, LP | - | - | - | -78,000 | -100.00% | - | Jun 30, 2024 |
| ALPHA DNA INVESTMENT MANAGEMENT LLC | - | - | - | -70,323 | -100.00% | - | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | - | - | - | -58,601 | -100.00% | - | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | - | - | - | -56,681 | -100.00% | - | Jun 30, 2024 |
| ALPS ADVISORS INC | - | - | - | -53,672 | -100.00% | - | Jun 30, 2024 |
| NEW YORK LIFE INVESTMENT MANAGEMENT LLC | - | - | - | -47,105 | -100.00% | - | Jun 30, 2024 |
| CAPSTONE INVESTMENT ADVISORS, LLC | - | - | - | -37,421 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -35,901 | -100.00% | - | Jun 30, 2024 |
| BAYESIAN CAPITAL MANAGEMENT, LP | - | - | - | -22,935 | -100.00% | - | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -15,205 | -100.00% | - | Jun 30, 2024 |
| TWINBEECH CAPITAL LP | - | - | - | -14,718 | -100.00% | - | Jun 30, 2024 |
| VONTOBEL HOLDING LTD. | - | - | - | -12,800 | -100.00% | - | Jun 30, 2024 |
| NEBULA RESEARCH & DEVELOPMENT LLC | - | - | - | -12,698 | -100.00% | - | Jun 30, 2024 |
| QUARRY LP | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| NVERSES CAPITAL, LLC | - | - | - | -4,200 | -100.00% | - | Jun 30, 2024 |
| ENTRYPOINT CAPITAL, LLC | - | - | - | -4,101 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -3,743 | -100.00% | - | Jun 30, 2024 |
| FIDELIS CAPITAL PARTNERS, LLC | - | - | - | -1,416 | -100.00% | - | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | - | - | - | -1,400 | -100.00% | - | Jun 30, 2024 |
| MACROVIEW INVESTMENT MANAGEMENT LLC | - | - | - | -997 | -100.00% | - | Jun 30, 2024 |
| HEADLANDS TECHNOLOGIES LLC | - | - | - | -302 | -100.00% | - | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | - | - | - | -100 | -100.00% | - | Jun 30, 2024 |
| SYSTM WEALTH SOLUTIONS LLC | - | - | - | -66 | -100.00% | - | Jun 30, 2024 |
| VERSANT CAPITAL MANAGEMENT, INC | - | - | - | -61 | -100.00% | - | Jun 30, 2024 |
| PRIVATE WEALTH MANAGEMENT GROUP, LLC | - | - | - | -58 | -100.00% | - | Jun 30, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | - | - | - | -19 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -14 | -100.00% | - | Jun 30, 2024 |
Travere Therapeutics's largest sold out institutional shareholder by shares sold is AFFINITY ASSET ADVISORS, LLC, sold -0.13M shares, valued at -, as of undefined.
Travere Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| FORUM FUNDS | 1.73% | 4,000,000 | - | - | Jan 31, 2024 |
| GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC | 0.95% | 750,000 | - | - | Dec 29, 2023 |
| Delaware Enhanced Global Dividend & Income Fund | 0.80% | 294,000 | - | - | Feb 28, 2023 |
| DELAWARE GROUP EQUITY FUNDS IV | 0.63% | 735,000 | - | - | Mar 28, 2024 |
| TETON WESTWOOD FUNDS | 0.54% | 350,000 | - | - | Dec 29, 2023 |
| BANCROFT FUND LTD | 0.50% | 700,000 | - | - | Dec 29, 2023 |
| DELAWARE INVESTMENTS DIVIDEND & INCOME FUND, INC | 0.48% | 127,000 | - | - | Feb 28, 2023 |
| ELLSWORTH GROWTH & INCOME FUND LTD | 0.36% | 500,000 | - | - | Dec 29, 2023 |
| TEKLA LIFE SCIENCES INVESTORS | 0.33% | 156,418 | - | - | Mar 31, 2024 |
| TEKLA HEALTHCARE INVESTORS | 0.31% | 262,102 | - | - | Mar 31, 2024 |
| Vanguard Montgomery Funds | 0.22% | 51,880 | - | - | Mar 31, 2024 |
| BlackRock Health Sciences Trust II | 0.15% | 394,274 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.10% | 54,050 | - | - | Mar 31, 2024 |
| ROYCE MICRO-CAP TRUST, INC. | 0.10% | 47,573 | 5,932 | 14.25% | Mar 31, 2024 |
| Humankind Benefit Corp | 0.09% | 1,911 | 1,094 | 133.90% | Dec 31, 2023 |
| DEUTSCHE DWS INVESTMENT TRUST | 0.08% | 241,387 | - | - | Mar 31, 2024 |
| BUFFALO FUNDS | 0.08% | 500,000 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS VARIABLE SERIES I | 0.07% | 26,114 | - | - | Mar 31, 2024 |
| DELAWARE GROUP EQUITY FUNDS V | 0.06% | 3,593,175 | -14,596 | -0.40% | Feb 29, 2024 |
| VANGUARD EXPLORER FUND | 0.05% | 627,587 | 326,829 | 108.67% | Jan 31, 2024 |
| Voya EQUITY TRUST | 0.05% | 71,980 | 71,980 | - | Feb 29, 2024 |
| VANGUARD HORIZON FUNDS | 0.04% | 1,011,896 | 97,010 | 10.60% | Mar 31, 2024 |
| DEUTSCHE DWS GLOBAL/INTERNATIONAL FUND, INC. | 0.03% | 75,542 | - | - | Mar 31, 2024 |
| ETFis Series Trust I | 0.03% | 37,798 | 19,817 | 110.21% | Jan 31, 2024 |
| DELAWARE VIP TRUST | 0.02% | 77,000 | - | - | Mar 28, 2024 |
| Federated Hermes MDT Series | 0.02% | 52,167 | - | - | Jan 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.02% | 130,146 | -5,773 | -4.25% | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.02% | 11,110 | - | - | Mar 31, 2024 |
| FRANKLIN STRATEGIC SERIES | 0.02% | 133,723 | - | - | Jan 31, 2024 |
| LAZARD FUNDS INC | 0.02% | 634,000 | - | - | Mar 31, 2024 |
| JANUS INVESTMENT FUND | 0.01% | 3,771,905 | - | - | Dec 31, 2023 |
| VALUED ADVISERS TRUST | 0.01% | 11,049 | - | - | Jan 31, 2024 |
| EATON VANCE GROWTH TRUST | 0.01% | 121,514 | - | - | Feb 29, 2024 |
| DELAWARE GROUP EQUITY FUNDS V | 0.01% | 602,000 | - | - | Feb 29, 2024 |
| FINANCIAL INVESTORS TRUST | 0.01% | 698,168 | 361,459 | 107.35% | Jan 31, 2024 |
| VANGUARD QUANTITATIVE FUNDS | 0.01% | 39,400 | -16,798 | -29.89% | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.01% | 3,379,388 | -977,634 | -22.44% | Mar 31, 2024 |
| DEUTSCHE DWS VARIABLE SERIES II | 0.01% | 18,778 | - | - | Mar 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.01% | 22,381 | - | - | Feb 29, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 1,469 | - | - | Mar 31, 2024 |
| IndexIQ ETF Trust | 0.01% | 14,198 | -1,278 | -8.26% | Jan 31, 2024 |
| Oaktree Diversified Income Fund Inc. | 0.00% | 16,000 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 197,445 | -30,258 | -13.29% | Jan 31, 2024 |
| Weiss Strategic Interval Fund | 0.00% | 15,448 | 15,448 | - | Sep 30, 2022 |
| TIAA-CREF LIFE FUNDS | 0.00% | 12,598 | 4,785 | 61.24% | Mar 31, 2024 |
| DELAWARE VIP TRUST | 0.00% | 16,202 | -397 | -2.39% | Mar 28, 2024 |
| ALPS ETF Trust | 0.00% | 50,625 | -2,358 | -4.45% | Feb 29, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND IV | 0.00% | 892,000 | - | - | Jan 31, 2024 |
| PFM Multi-Manager Series Trust | 0.00% | 3,004 | - | - | Dec 31, 2023 |
| FIRST TRUST EXCHANGE-TRADED ALPHADEX FUND | 0.00% | 13,706 | - | - | Jan 31, 2024 |
| JOHN HANCOCK INVESTMENT TRUST | 0.00% | 293,254 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 698,267 | 47,448 | 7.29% | Feb 29, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 101,048 | 71,668 | 243.93% | Mar 31, 2024 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 152,336 | 45,990 | 43.25% | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 35,222 | 398 | 1.14% | Mar 31, 2024 |
| Fidelity Commonwealth Trust II | 0.00% | 19,110 | -8,832 | -31.61% | Aug 31, 2023 |
| Calvert Variable Products, Inc. | 0.00% | 7,238 | - | - | Mar 31, 2024 |
| Direxion Shares ETF Trust | 0.00% | 412,055 | 127,818 | 44.97% | Jan 31, 2024 |
| SSGA FUNDS | 0.00% | 1,155 | - | - | Feb 29, 2024 |
| ProFunds | 0.00% | 30,785 | 6,117 | 24.80% | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.00% | 167,028 | - | - | Feb 29, 2024 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 10,474 | - | - | Mar 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 40,099 | -2,126 | -5.03% | Mar 31, 2024 |
| JPMORGAN INSURANCE TRUST | 0.00% | 26,711 | -1,089 | -3.92% | Mar 31, 2023 |
| Ivy Variable Insurance Portfolios | 0.00% | 45,214 | -2,373 | -4.99% | Mar 28, 2024 |
| AMG FUNDS III | 0.00% | 9,474 | - | - | Mar 28, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 45,611 | -3,637 | -7.39% | Mar 31, 2024 |
| CLEARWATER INVESTMENT TRUST | 0.00% | 12,948 | - | - | Mar 28, 2024 |
| Franklin Alternative Strategies Funds | 0.00% | 732,000 | 242,000 | 49.39% | Feb 29, 2024 |
| OHIO NATIONAL FUND INC | 0.00% | 23,811 | - | - | Mar 31, 2024 |
| THRIVENT MUTUAL FUNDS | 0.00% | 101,967 | - | - | Mar 28, 2024 |
| MFS VARIABLE INSURANCE TRUST III | 0.00% | 17,780 | - | - | Mar 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 255,076 | 26,450 | 11.57% | Feb 29, 2024 |
| BlackRock ETF Trust | 0.00% | 924 | - | - | Jan 31, 2024 |
| Series Portfolios Trust | 0.00% | 6,130 | - | - | Jan 31, 2024 |
| DELAWARE GROUP FOUNDATION FUNDS | 0.00% | 4,689 | 125 | 2.74% | Dec 30, 2022 |
| BMO FUNDS, INC. | 0.00% | 34,698 | - | - | Nov 30, 2021 |
| ETF Managers Trust | 0.00% | 6,419 | - | - | Dec 31, 2023 |
| THRIVENT SERIES FUND INC | 0.00% | 91,839 | - | - | Mar 28, 2024 |
| PUTNAM ASSET ALLOCATION FUNDS | 0.00% | 25,936 | - | - | Mar 31, 2024 |
| NEW COVENANT FUNDS | 0.00% | 3,434 | - | - | Dec 31, 2023 |
| Principal Exchange-Traded Funds | 0.00% | 8,996 | -740 | -7.60% | Mar 31, 2024 |
| Columbia Funds Variable Series Trust II | 0.00% | 23,137 | - | - | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 3,505 | - | - | Mar 31, 2024 |
| Global X Funds | 0.00% | 29,936 | - | - | Jan 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 14,734 | 251 | 1.73% | Mar 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 361,177 | 21,344 | 6.28% | Feb 29, 2024 |
| PRUDENTIAL INVESTMENT PORTFOLIOS, INC. | 0.00% | 5,600 | - | - | Mar 28, 2024 |
| Voya INVESTORS TRUST | 0.00% | 28,443 | -2,108 | -6.90% | Mar 31, 2024 |
| SEASONS SERIES TRUST | 0.00% | 9,481 | -527 | -5.27% | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 24,998 | 1,000 | 4.17% | Mar 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 30,487 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 42,572 | 1,151 | 2.78% | Mar 28, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.00% | 23,297 | -730,647 | -96.91% | Jan 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 243,362 | - | - | Jan 31, 2024 |
| SA FUNDS INVESTMENT TRUST | 0.00% | 3,687 | - | - | Mar 31, 2024 |
| JPMORGAN TRUST II | 0.00% | 233,700 | - | - | Feb 29, 2024 |
| TIAA-CREF FUNDS | 0.00% | 678,317 | 230,920 | 51.61% | Jan 31, 2024 |
| Forethought Variable Insurance Trust | 0.00% | 894 | - | - | Mar 28, 2024 |
| COLUMBIA FUNDS VARIABLE INSURANCE TRUST | 0.00% | 117,682 | -3,100 | -2.57% | Mar 31, 2024 |
Travere Therapeutics's largest mutual fund holder by % of total assets is "FORUM FUNDS", owning 4.00M shares, compromising 1.73% of its total assets.
Travere Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 52 | -70.95% |
| 31 Mar, 24 | 179 | 2.29% |
| 31 Dec, 23 | 175 | -7.41% |
| 30 Sep, 23 | 189 | 9.25% |
| 30 Jun, 23 | 173 | -2.26% |
| 31 Mar, 23 | 177 | 12.74% |
| 31 Dec, 22 | 157 | -9.25% |
| 30 Sep, 22 | 173 | - |
| 30 Jun, 22 | 173 | -0.57% |
| 31 Mar, 22 | 174 | -3.33% |
| 31 Dec, 21 | 180 | 16.13% |
| 30 Sep, 21 | 155 | 9.93% |
| 30 Jun, 21 | 141 | -9.03% |
| 31 Mar, 21 | 155 | 6.90% |
| 31 Dec, 20 | 145 | - |
As of 30 Jun 24, 52 institutions are holding Travere Therapeutics's shares, representing a decrease of -70.95% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 15,814,428 | -81.96% |
| 31 Mar, 24 | 87,677,449 | 2.46% |
| 31 Dec, 23 | 85,573,713 | 3.91% |
| 30 Sep, 23 | 82,354,299 | -0.88% |
| 30 Jun, 23 | 83,089,376 | -1.27% |
| 31 Mar, 23 | 84,155,300 | 15.48% |
| 31 Dec, 22 | 72,877,263 | 4.58% |
| 30 Sep, 22 | 69,684,139 | 0.32% |
| 30 Jun, 22 | 69,463,395 | -0.42% |
| 31 Mar, 22 | 69,756,589 | 6.00% |
| 31 Dec, 21 | 65,807,942 | 8.29% |
| 30 Sep, 21 | 60,772,812 | -0.73% |
| 30 Jun, 21 | 61,221,624 | -2.19% |
| 31 Mar, 21 | 62,590,331 | 19.77% |
| 31 Dec, 20 | 52,258,523 | - |
Travere Therapeutics (TVTX) has 15.81M shares outstanding as of 30 Jun 24, down -81.96% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 20.41% | 0.16% |
| 31 Mar, 24 | 113.67% | 0.91% |
| 31 Dec, 23 | 111.90% | 0.96% |
| 30 Sep, 23 | 107.93% | 0.90% |
| 30 Jun, 23 | 109.33% | 0.72% |
| 31 Mar, 23 | 123.44% | 0.94% |
| 31 Dec, 22 | 114.30% | 0.97% |
| 30 Sep, 22 | 108.82% | 0.91% |
| 30 Jun, 22 | 109.15% | 0.89% |
| 31 Mar, 22 | 110.49% | 0.91% |
| 31 Dec, 21 | 109.99% | 1.09% |
| 30 Sep, 21 | 100.61% | 0.98% |
| 30 Jun, 21 | 101.07% | 0.82% |
| 31 Mar, 21 | 111.24% | 1.07% |
| 31 Dec, 20 | 101.94% | - |
As of 30 Jun 24, Travere Therapeutics is held by 20.41% institutional shareholders, representing a 0.16% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 28 | -69.89% |
| 31 Mar, 24 | 93 | 3.33% |
| 31 Dec, 23 | 90 | -15.09% |
| 30 Sep, 23 | 106 | -4.50% |
| 30 Jun, 23 | 111 | -7.50% |
| 31 Mar, 23 | 120 | 42.86% |
| 31 Dec, 22 | 84 | -1.18% |
| 30 Sep, 22 | 85 | 11.84% |
| 30 Jun, 22 | 76 | -13.64% |
| 31 Mar, 22 | 88 | -3.30% |
| 31 Dec, 21 | 91 | 18.18% |
| 30 Sep, 21 | 77 | 6.94% |
| 30 Jun, 21 | 72 | -24.21% |
| 31 Mar, 21 | 95 | -31.65% |
| 31 Dec, 20 | 139 | - |
28 institutional shareholders have increased their position in TVTX stock as of 30 Jun 24 compared to 93 in the previous quarter (a -69.89% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 18 | -64.71% |
| 31 Mar, 24 | 51 | -5.56% |
| 31 Dec, 23 | 54 | 8.00% |
| 30 Sep, 23 | 50 | 21.95% |
| 30 Jun, 23 | 41 | 32.26% |
| 31 Mar, 23 | 31 | -42.59% |
| 31 Dec, 22 | 54 | - |
| 30 Sep, 22 | 54 | -20.59% |
| 30 Jun, 22 | 68 | 13.33% |
| 31 Mar, 22 | 60 | 13.21% |
| 31 Dec, 21 | 53 | -1.85% |
| 30 Sep, 21 | 54 | 25.58% |
| 30 Jun, 21 | 43 | 13.16% |
| 31 Mar, 21 | 38 | - |
| 31 Dec, 20 | - | - |
18 institutional shareholders have reduced their position in TVTX stock as of 30 Jun 24 compared to 51 in the previous quarter (a -64.71% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 52 | -70.95% | 15,814,428 | -81.96% | 20.41% | 0.16% | 28 | -69.89% | 18 | -64.71% |
| 31 Mar, 24 | 179 | 2.29% | 87,677,449 | 2.46% | 113.67% | 0.91% | 93 | 3.33% | 51 | -5.56% |
| 31 Dec, 23 | 175 | -7.41% | 85,573,713 | 3.91% | 111.90% | 0.96% | 90 | -15.09% | 54 | 8.00% |
| 30 Sep, 23 | 189 | 9.25% | 82,354,299 | -0.88% | 107.93% | 0.90% | 106 | -4.50% | 50 | 21.95% |
| 30 Jun, 23 | 173 | -2.26% | 83,089,376 | -1.27% | 109.33% | 0.72% | 111 | -7.50% | 41 | 32.26% |
| 31 Mar, 23 | 177 | 12.74% | 84,155,300 | 15.48% | 123.44% | 0.94% | 120 | 42.86% | 31 | -42.59% |
| 31 Dec, 22 | 157 | -9.25% | 72,877,263 | 4.58% | 114.30% | 0.97% | 84 | -1.18% | 54 | - |
| 30 Sep, 22 | 173 | - | 69,684,139 | 0.32% | 108.82% | 0.91% | 85 | 11.84% | 54 | -20.59% |
| 30 Jun, 22 | 173 | -0.57% | 69,463,395 | -0.42% | 109.15% | 0.89% | 76 | -13.64% | 68 | 13.33% |
| 31 Mar, 22 | 174 | -3.33% | 69,756,589 | 6.00% | 110.49% | 0.91% | 88 | -3.30% | 60 | 13.21% |
| 31 Dec, 21 | 180 | 16.13% | 65,807,942 | 8.29% | 109.99% | 1.09% | 91 | 18.18% | 53 | -1.85% |
| 30 Sep, 21 | 155 | 9.93% | 60,772,812 | -0.73% | 100.61% | 0.98% | 77 | 6.94% | 54 | 25.58% |
| 30 Jun, 21 | 141 | -9.03% | 61,221,624 | -2.19% | 101.07% | 0.82% | 72 | -24.21% | 43 | 13.16% |
| 31 Mar, 21 | 155 | 6.90% | 62,590,331 | 19.77% | 111.24% | 1.07% | 95 | -31.65% | 38 | - |
| 31 Dec, 20 | 145 | - | 52,258,523 | - | 101.94% | - | 139 | - | - | - |
Travere Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Travere Therapeutics's stock was made by Cline Christopher R. on Apr 12 2024, selling 54 shares at $6.74 per share (valued at $363.96).
Travere Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 18 | 1 | 1800.00% |
| Q1 2024 | 15 | 18 | 83.33% |
| Q4 2023 | - | 1 | - |
| Q3 2023 | 3 | 4 | 75.00% |
| Q2 2023 | 18 | 6 | 300.00% |
| Q1 2023 | 20 | 17 | 117.65% |
| Q4 2022 | - | 1 | - |
| Q3 2022 | 1 | 12 | 8.33% |
| Q2 2022 | 17 | 8 | 212.50% |
| Q1 2022 | 27 | 19 | 142.11% |
| Q4 2021 | 2 | 9 | 22.22% |
| Q3 2021 | 9 | 17 | 52.94% |
| Q2 2021 | 19 | 13 | 146.15% |
| Q1 2021 | 27 | 45 | 60.00% |
| Q4 2020 | 4 | 15 | 26.67% |
| Q3 2020 | 6 | 12 | 50.00% |
| Q2 2020 | 18 | 15 | 120.00% |
| Q1 2020 | 28 | 12 | 233.33% |
| Q4 2019 | 2 | 1 | 200.00% |
| Q3 2019 | - | 2 | - |
18 total buy trades, and 1 total sell trades (buy/sell ratio of 18.00%) were made by Travere Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | 1 | - |
| Q1 2024 | - | 18 | - |
| Q4 2023 | - | 1 | - |
| Q3 2023 | - | 4 | - |
| Q2 2023 | - | 6 | - |
| Q1 2023 | - | 17 | - |
| Q4 2022 | - | 1 | - |
| Q3 2022 | - | 1 | - |
| Q2 2022 | - | 8 | - |
| Q1 2022 | - | 19 | - |
| Q4 2021 | - | 7 | - |
| Q3 2021 | - | 7 | - |
| Q2 2021 | - | 12 | - |
| Q1 2021 | - | 42 | - |
| Q4 2020 | - | 14 | - |
| Q3 2020 | - | 12 | - |
| Q2 2020 | - | 15 | - |
| Q1 2020 | - | 12 | - |
| Q4 2019 | - | 1 | - |
| Q3 2019 | - | 2 | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 1 open market sell trades of Travere Therapeutics's stocks.
Travere Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| ANAB | AnaptysBio, Inc. |
| DICE | DICE Therapeutics, Inc. |
| NUVL | Nuvalent, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| APLS | Apellis Pharmaceuticals, Inc. |
| MGTX | MeiraGTx Holdings plc |
| STOK | Stoke Therapeutics, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| RNA | Avidity Biosciences, Inc. |
| COGT | Cogent Biosciences, Inc. |
| LEGN | Legend Biotech Corporation |
| KROS | Keros Therapeutics, Inc. |
| GPCR | Structure Therapeutics Inc. |
| PCVX | Vaxcyte, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| CYTK | Cytokinetics, Incorporated |
| FIXX | Q32 Bio Inc. |
TVTX Ownership FAQ
Who Owns Travere Therapeutics?
Travere Therapeutics is owned by institutional shareholders (20.41%), insiders (0.73%), and public (78.87%). The largest institutional shareholder of Travere Therapeutics is BLACKROCK INC. (9.86% of total shares) and the top mutual fund owner is FORUM FUNDS (1.73% of total shares).
Who are the major institutional shareholders of Travere Therapeutics?
Travere Therapeutics's major institutional shareholders are BLACKROCK INC., ARMISTICE CAPITAL, LLC, DEEP TRACK CAPITAL, LP, VANGUARD GROUP INC, and ROCK SPRINGS CAPITAL MANAGEMENT LP. The top five shareholders own together 43.38% of the company's share outstanding.
How many Travere Therapeutics shareholders are there?
As of Jun 2024, there are 52 institutional shareholders of Travere Therapeutics.
What percentage of Travere Therapeutics is owned by BLACKROCK INC?
BLACKROCK INC owns 7.64M shares of Travere Therapeutics, representing 9.86% of the company's total shares outstanding, valued at $62.84M (as of Jun 2024).
What percentage of Travere Therapeutics is owned by ARMISTICE CAPITAL, LLC?
As of Jun 2024, ARMISTICE CAPITAL, LLC holds 7.5M shares of Travere Therapeutics (TVTX), compromising 9.68% of the company, valued at $61.65M.
What percentage of Travere Therapeutics is owned by DEEP TRACK CAPITAL, LP?
DEEP TRACK CAPITAL, LP is the third largest holder of Travere Therapeutics. The company owns 7.37M of the company's shares outstanding (worth $60.58M).